Dr. David Rabin, a board-certified psychiatrist and translational neuroscientist, is the Chief Innovation Officer, Co-Founder, and Co-Inventor at Apollo Neuroscience, Inc. and has been studying resilience and the impact of chronic stress in humans for over a decade. Dr. Rabin has also organized the world’s largest controlled study of psychedelic medicines in collaboration with colleagues at Yale, the University of Southern California, Modern Spirit, and MAPS (Multidisciplinary Association of Psychedelic Studies) to determine the mechanisms of the dramatic therapeutic benefits observed following psychedelic-assisted psychotherapy in treatment-resistant mental illness.